Insider Selling: Q32 Bio (NASDAQ:QTTB) Insider Sells 2,815 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) insider Shelia Violette sold 2,815 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $12,695.65. Following the completion of the transaction, the insider owned 55,569 shares in the company, valued at approximately $250,616.19. This represents a 4.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Q32 Bio Stock Performance

NASDAQ:QTTB traded down $0.20 on Friday, hitting $4.56. 203,990 shares of the stock were exchanged, compared to its average volume of 164,705. The stock has a market capitalization of $56.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. The company’s 50-day moving average price is $3.78 and its 200 day moving average price is $2.88. Q32 Bio Inc. has a 52 week low of $1.35 and a 52 week high of $6.37.

Trending Headlines about Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Institutional Investors Weigh In On Q32 Bio

Several large investors have recently modified their holdings of QTTB. Monaco Asset Management SAM raised its position in shares of Q32 Bio by 17.1% during the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock worth $882,000 after purchasing an additional 86,486 shares during the period. Opaleye Management Inc. acquired a new position in shares of Q32 Bio in the 4th quarter valued at approximately $708,000. Geode Capital Management LLC increased its stake in Q32 Bio by 19.9% during the 4th quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock worth $352,000 after purchasing an additional 17,617 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Q32 Bio by 110.6% during the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock worth $331,000 after buying an additional 52,300 shares during the period. Finally, Jane Street Group LLC bought a new position in Q32 Bio in the second quarter valued at approximately $69,000. 31.32% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

QTTB has been the topic of several recent research reports. HC Wainwright started coverage on Q32 Bio in a research report on Wednesday. They issued a “buy” rating and a $13.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $14.00.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.